Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COmparison of Bleeding Risk between Rivaroxaban and Apixaban for the treatment of acute venous thromboembolism
2023-504179-26-00Phase 4Completed
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised trial in Acute Venous Thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) comparing Rivaroxaban (Xarelto) with Apixaban (Eliquis) (2 arms). Primary endpoint: Clinically relevant bleeding (CRB). Started Jun 2023; status: completed.
02
Drugs
rivaroxabanapixaban
03
Conditions
Acute Venous Thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2023-504179-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504179-26-00.